News

The European Commission has granted late stage cell therapy company Cytori Therapeutics, Inc.’s ECCS-50 cellular therapy the designation of orphan medicinal product for the treatment of scleroderma. The decision, which was made due to positive references from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products, represents the first time an…

A study recently published in the on-line journal Clinical and Experimental Rheumatology is challenging the clinical assumptions that morphea and systemic sclerosis (SSc) should be considered the part of the same disease spectrum.  The study, entitled, “Prospective evaluation of frequency of signs of systemic sclerosis…

Researchers from the University of Cologne in Germany showed that Systemic sclerosis-overlap Syndrome should be regarded as different separate subset in Systemic sclerosis (SSc) patients. The study entitled “Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis” appeared on…

A recent study published in the journal PLOS One reports the results of a comprehensive clinical assessment review in patients with Systemic sclerosis and lung cancer. Systemic sclerosis (SSc) is a connective tissue disorder characterized by immune dysregulation and accumulation of extracellular matrix constituents resulting in…

A case study of a patient with Scleroderma recently published in the journal JAAD Case Reports reports the clinical outcomes of treatment with HDAC (Histone deacetylase inhibition) with divalproex sodium. Scleroderma is a complex autoimmune connective tissue disease, and although the causes remain unclear, research suggests that transforming growth…